Leukotriene B

1. A compound of formula (I):

wherein:

R 1 and R 2 , independently of each other, are

halogen,

benzo[1,3]dioxole, unsubstituted or mono- or bi-substituted with halogen,

2,3-dihydro-benzo[1,4]dioxine, unsubstituted or mono- or bi-substituted with halogen,

3,4-dihydro-2H-benzo[b][1,4]dioxepine, unsubstituted or mono- or bi-substituted with halogen

monocyclic 5- or 6-membered aryl or monocyclic 5- or 6-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ;

bicyclic 8- to 12-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ;

X is O, C, S, or N, unsubstituted or substituted with lower alkyl; and

a is a single bond or an alkynyl bond,

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , wherein:

R 1 and R 2 , independently of each other, are benzo[1,3]dioxole, 2,3-dihydro-benzo[1,4]dioxine or 3,4-dihydro-2H-benzo[b][1,4]dioxepine; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 , wherein:

R 1 and R 2 , independently of each other, are bicyclic 8- to 12-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

4. The compound according to claim 1 , wherein:

R 1 is benzo[1,3]dioxole, 2,3-dihydro-benzo[1,4]dioxine or 3,4-dihydro-2H-benzo[b][1,4]dioxepine;

R 2 is monocyclic 5- or 6-membered aryl or monocyclic 5- or 6-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

5. The compound according to claim 1 , wherein:

R 1 is benzo[1,3]dioxole, 2,3-dihydro-benzo[1,4]dioxine or 3,4-dihydro-2H-benzo[b][1,4]dioxepine;

R 2 is bicyclic 8- to 12-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

6. The compound according to claim 1 , wherein R 1 and/or R 2 is benzo[1,3]dioxole, 2,3-dihydro-benzo[1,4]dioxine or 3,4-dihydro-2H-benzo[b][1,4]dioxepine.

7. The compound according to claim 1 , wherein said bicyclic 8- to 12-membered heteroaryl is 5-indolyl or 5-quinolinyl.

8. The compound according to claim 1 , wherein:

R 1 and R 2 , independently of each other, are monocyclic 5- or 6-membered aryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

9. The compound according to claim 1 , wherein:

R 1 and R 2 , independently of each other, are monocyclic 5- or 6-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

10. The compound according to claim 1 , wherein:

R 1 is monocyclic 5- or 6-membered aryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ;

R 2 or monocyclic 5- or 6-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

11. The compound according to claim 1 , wherein:

R 1 is monocyclic 5- or 6-membered heteroaryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ;

R 2 is monocyclic 5- or 6-membered aryl, unsubstituted or substituted with one to four substituents selected from the group consisting of halogen, lower alkyl, haloloweralkyl, carboxy, alkoxy, hydroxy, aminoloweralkyl and —OCF 3 ; and

X is O, C, S, or N, unsubstituted or substituted with lower alkyl,

and pharmaceutically acceptable salts thereof.

12. The compound according to claim 1 , wherein R 1 and/or R 2 is phenyl.

13. The compound according to claim 1 , wherein R 1 and/or R 2 is pyridine, pyrimidine or thiophene.

14. The compound according to claim 1 , wherein X is O or N.

15. The compound according to claim 1 , wherein said compound is:

4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-pyridin-4-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-[3-{6-[3,5-Bis-(2-fluoro-pyridin-4-yl)-phenoxy]-hexyl}-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3′-fluoro-5-pyridin-4-yl -biphenyl-3-yloxy)-hexyl]-phenoxy}-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3-pyridin-4-yl-5-thiophen-3-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-([1,1′;3′,1″]terphenyl-5′-yloxy)-hexyl]-phenoxy}-butyric acid,

4-[3-[6-(3-Benzo[1,3]dioxol-5-yl-5-thiophen-3-yl-phenoxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-[3-[6-(3-Benzo[1,3]dioxol -5-yl-5-pyridin-4-yl-phenoxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-(2-(2-Carboxy-ethyl)-3-{6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-4-yl-phenoxy]-hexyl}-phenoxy)-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(2-fluoro-[1,1′;3′,1″]terphenyl-5′-yloxy)-hexyl]-phenoxy}-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(5-thiophen-3-yl-biphenyl-3-yloxy)-hexyl]-phenoxy}-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3-pyrimidin-5-yl-5-thiophen-3-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-[3-[6-(3-Benzo[1,3]dioxol-5-yl-5-pyrimidin-5-yl-phenoxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(4″-dimethylamino-4-fluoro-3-methyl-[1,1′;3′,1″]terphenyl-5′-yloxy)-hexyl]-phenoxy}-butyric acid,

4-(2-(2-Carboxy-ethyl)-3-{6-[3-(2-chloro-pyridin-4-yl)-5-thiophen-3-yl-phenoxy]-hexyl}-phenoxy)-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-thiophen-3-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-[3-[6-(5-Benzo[1,3]dioxol-5-yl-biphenyl-3-yloxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-[3-[6-(5-Benzo[1,3]dioxol-5-yl-2″-fluoro-biphenyl-3-yloxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-pyridin-3-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-pyridin-2-yl-phenoxy)-hexyl]-phenoxy}-butyric acid,

4-[3-[6-(5-Benzo[1,3]dioxol-5-yl-3′-fluoro-biphenyl-3-yloxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid, or

4-[3-[7-(3,5-Bis-benzo[1,3]dioxol-5-yl-phenyl)-heptyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid.

16. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.